# Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients | This GLP In 182 patients switching to tirzepatide, a liver fibrosis index fell significantly only in the high-risk group, with baseline severity correlated to the size of the change. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-fibrosis-worst-group Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients Switching to tirzepatide improved a fibrosis score only in the patients whose scores were worst to begin with. That is a real effect or regression to the mean. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 After switching to tirzepatide, six months · steatosis index · low risk · high risk · fell in both groups · fibrosis index · low risk · high risk · fell in the high-risk group only · 182 patients, all of whom switched. No one stayed put. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 182 people with type 2 diabetes at high risk of fatty liver disease switched from a GLP-1 drug to tirzepatide. - Over six months, blood sugar, weight and liver enzymes all improved. - The steatosis index fell in both risk groups; the fibrosis index fell significantly only in the high-risk group, P < 0.001. - Baseline steatosis correlated with the change in the fibrosis index, rho 0.234, P = 0.005. - Nobody stayed on their original drug, so there is no comparison group. A result that shows up only in the group with the worst starting numbers is the one to slow down on, because two very different things produce exactly that picture — and this study has no arm that could tell them apart, which is [what a missing comparator costs](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## What was done A secondary analysis of a multicenter Japanese cohort, looking at the 182 patients at high risk of metabolic dysfunction-associated steatotic liver disease who switched from a GLP-1 receptor agonist to tirzepatide. [\[1\]](https://thisglp.com/research/tirzepatide-fibrosis-worst-group#ref-1) Two calculated scores were tracked over six months: the Hepatic Steatosis Index and the Fibrosis-4 index, both assembled from routine measurements rather than from imaging or a biopsy. Patients were split into low- and high-risk groups by baseline fibrosis status. Everyone switched. There is no group that stayed on the original drug, which is the design difference between this and [a study that checked whether its own method could detect anything](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). ## What improved Glycated hemoglobin, body weight and liver enzymes all fell significantly. The steatosis index fell in both risk groups. The fibrosis index fell significantly only in the high-risk group, P < 0.001. And baseline steatosis was positively correlated with the change in the fibrosis index, rho = 0.234, P = 0.005 — the worse a person started, the more their score moved. Two things that look identical here The first is a real effect concentrated in sicker patients, which is plausible: there is more fibrosis to improve when there is more of it to begin with. The second is regression to the mean — pick out the people whose scores were most extreme at one measurement and they will, on average, be less extreme at the next, whatever you do to them in between. A correlation of 0.234 is weak in either case, significant across 182 patients and explaining a small share of what happened. With no group that stayed put, nothing in this design separates the two. ## The claim worth noting The authors report that improvements in the hepatic indices were not correlated with changes in body mass index or glycated hemoglobin, and describe the benefit as not clearly explained by weight change. That is their phrasing and it is the interesting part, because it points at something the weight loss does not account for. It also sits in a study with no control arm, which is a weak place to establish a mechanism — the same limit as [the surgery comparison where more weight bought no more stiffness improvement](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness). ## What a reader takes from it Not a reason to switch. Nobody in this study chose tirzepatide from a price page, and a before-and-after in 182 people who all did the same thing is the weakest form of comparison there is. What is worth keeping is the check: when an effect appears only in the subgroup that started worst, ask what the people who started worst would have done anyway. It applies here, and it applies to every [index calculated from routine bloods](https://thisglp.com/research/glp1-pcos-insulin-resistance) that somebody has sorted patients by. ## Frequently asked Does switching to tirzepatide help the liver? Scores improved over six months in these 182 patients, but nobody stayed on their original drug, so there is no comparison group and no way to know what would have happened anyway. Why does 'only in the high-risk group' matter? Because selecting people with the most extreme scores guarantees that, on average, their next measurement is less extreme. That looks identical to a real effect concentrated in sicker patients. Was the improvement due to weight loss? The authors report it was not correlated with changes in body mass index or glycated hemoglobin, and describe it as not clearly explained by weight change. Were these liver scans? No. Both the steatosis and fibrosis measures are indices calculated from routine clinical measurements, not imaging or biopsy. ## Sources 1. \[1\] Takiyama T, et al. (2026). Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study Journal of Diabetes and Its Complications. [PMID 42618422](https://pubmed.ncbi.nlm.nih.gov/42618422/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)